68Ga-pentixafor is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Zhongnan Hospital (1) and First Affiliated Hospital of Fujian Medical University (1). Registered phases: Not applicable and Phase EARLY_PHASE1. Conditions studied include CXCR4; PET/CT; Hematological Malignancy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04504526 | Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases (ClinicalTrials.gov ↗) Lymphoma, Multiple Myeloma, Leukemia |
Phase EARLY_PHASE1 | Recruiting |
| NCT05255926 | CXCR4-targeted PET/CT Imaging in Hematological Malignancies (ClinicalTrials.gov ↗) CXCR4, PET/CT, Hematological Malignancy |
Not applicable | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| CXCR4 | 1 |
| PET/CT | 1 |
| Hematological Malignancy | 1 |
| Lymphoma | 1 |
| Multiple Myeloma | 1 |
| Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Zhongnan Hospital | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Register | 68Ga-pentixafor trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 68Ga-pentixafor works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 68Ga-pentixafor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.